Cancer of the corpus uteri

Abstract

Endometrial cancer is the most common gynecological malignancy in high‐income countries. Although the overall prognosis is relatively good, high‐grade endometrial cancers have a tendency to recur. Recurrence needs to be prevented since the prognosis for recurrent endometrial cancer is dismal. Treatment tailored to tumor biology is the optimal strategy to balance treatment efficacy against toxicity. Standard treatment consists of hysterectomy and bilateral salpingo‐oophorectomy. Lymphadenectomy (with ongoing studies of sentinel node biopsy) enables identification of lymph node positive patients who need adjuvant treatment, including radiotherapy and chemotherapy. Adjuvant radiotherapy is used for Stage I–II patients with high‐risk factors and Stage III lymph node negative patients. In advanced disease, a combination of surgery to no residual disease and chemotherapy results in the best outcome. Surgery for recurrent disease is only advocated in patients with a good performance status with a relatively long disease‐free interval.

Uterine Clear Cell Carcinoma: Does Adjuvant Chemotherapy Improve Outcomes?

“…14 All histological diagnoses were reviewed by a subspecialist gynecologic pathologist and classified according to the World Health Organization classification. 16 We excluded patients for whom the operative note or clinical notes were not available for review, or those who had their postoperative follow-up in another hospital. Patients who had clear cell carcinoma of the ovary or any concomitant cancers were excluded.…”

Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study

“…1 These carcinomas are traditionally divided into endometrioid and nonendometrioid endometrial carcinomas, based on their histology. 1,2 Endometrioid carcinomas are assumed to arise from hyperplastic endometrium under the influence of unopposed estrogen stimulation and generally have a favorable prognosis. 1 Nonendometrioid carcinomas on the other hand are assumed to arise from atrophic endometrium less dependent of estrogen stimulation and have a worse outcome.…”

“…1,2 Endometrioid carcinomas are assumed to arise from hyperplastic endometrium under the influence of unopposed estrogen stimulation and generally have a favorable prognosis. 1 Nonendometrioid carcinomas on the other hand are assumed to arise from atrophic endometrium less dependent of estrogen stimulation and have a worse outcome. 1 Primary treatment for endometrial carcinomas consists of a hysterectomy and bilateral salpingo-oophorectomy, and additionally a lymphadenectomy in high-grade endometrioid and nonendometrioid carcinomas.…”

“…1 Nonendometrioid carcinomas on the other hand are assumed to arise from atrophic endometrium less dependent of estrogen stimulation and have a worse outcome. 1 Primary treatment for endometrial carcinomas consists of a hysterectomy and bilateral salpingo-oophorectomy, and additionally a lymphadenectomy in high-grade endometrioid and nonendometrioid carcinomas. Adjuvant treatment is recommended based on the International Federation of Gynecology and Obstetrics (FIGO) stage, histological type, tumor grade, myometrial invasion, lymphovascular space invasion (LVSI), and the age of the patient.…”

Metastatic endometrial endometrioid carcinoma mimicking pilomatrixoma of the distal vagina

“…We present the case of a woman aged 55 years with a history of endometrial endometrioid carcinoma, FIGO5 stage 1A grade 2, treated with total laparoscopic hysterectomy and bilateral salpingo-oopherectomy in 2012. No adjuvant treatment was given.…”